SCHEMBL21753343

SCHEMBL21753343

Cn1cc(-c2ccc(CO)nc2)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.44
GPR55 Q9Y2T6 1/20 0.43
CCNC P24863 2/20 0.42
CDK8 P49336 2/20 0.42
PDK2 Q15119 1/20 0.42
MKNK1 Q9BUB5 1/20 0.41
MKNK2 Q9HBH9 1/20 0.41
LRRK2 Q5S007 1/20 0.41
GSK3B P49841 1/20 0.41
DYRK1A Q13627 1/20 0.41
CLK1 P49759 1/20 0.41
FYN P06241 2/20 0.40
PIK3CA P42336 1/20 0.40
PI4KA P42356 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
MAP4K4 O95819 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
ACVR1 Q04771 1/20 0.40
EP300 Q09472 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17212043 0.85 MAPT (0.45) MAPTGPR55PDK2MKNK1MKNK2
SCHEMBL15729483 0.83 PRMT5 (0.49) MAPTGPR55CCNCCDK8PDK2
SCHEMBL21769966 0.83 MAPT (0.44) MAPTGPR55PDK2MKNK1MKNK2
Hydrochloric Acid SCHEMBL17091012 0.82 PRMT5 (0.48) MAPTGPR55CCNCCDK8PDK2
Hydrochloric Acid SCHEMBL17090879 0.82 PRMT5 (0.48) MAPTGPR55CCNCCDK8PDK2
SCHEMBL28508293 0.80 MET (0.50) CCNCCDK8MKNK1MKNK2LRRK2
SCHEMBL17091406 0.78 CLK1 (0.47) CLK1MAP4K4EP300
SCHEMBL12516034 0.77 EPHB4 (0.50) CCNCCDK8PDK2MKNK1MKNK2
SCHEMBL30519697 0.77 MAPT (0.47) MAPTGPR55PDK2MKNK1MKNK2
SCHEMBL27252273 0.77 MAPT (0.47) MAPTGPR55PDK2MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 US disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 WO disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP MAPT 22/4885GPR55 4244/4885CCNC 2351/4885
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS PREP, GAA, DNPEP MAPT 24/4885GPR55 4294/4885CCNC 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.